🇺🇸 FDA
Pipeline program

Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab

Probiotic in AL amyloidosis

Phase 3 small_molecule active

Quick answer

Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab for Immunoglobulin Light-chain Amyloidosis is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Immunoglobulin Light-chain Amyloidosis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials